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Abstract
Rationale: Previous in vitro research demonstrated that ascorbate enhances potency and duration of activity of agonists
binding to alpha 1 adrenergic and histamine receptors.
Objectives: Extending this work to beta 2 adrenergic systems in vitro and in vivo.
Methods: Ultraviolet spectroscopy was used to study ascorbate binding to adrenergic receptor preparations and peptides.
Force transduction studies on acetylcholine-contracted trachealis preparations from pigs and guinea pigs measured the
effect of ascorbate on relaxation due to submaximal doses of beta adrenergic agonists. The effect of inhaled albuterol with
and without ascorbate was tested on horses with heaves and sheep with carbachol-induced bronchoconstriction.
Measurements: Binding constants for ascorbate binding to beta adrenergic receptor were derived from concentration-
dependent spectral shifts. Dose- dependence curves were obtained for the relaxation of pre-contracted trachealis
preparations due to beta agonists in the presence and absence of varied ascorbate. Tachyphylaxis and fade were also
measured. Dose response curves were determined for the effect of albuterol plus-and-minus ascorbate on airway resistance
in horses and sheep.
Main Results: Ascorbate binds to the beta 2 adrenergic receptor at physiological concentrations. The receptor recycles
dehydroascorbate. Physiological and supra-physiological concentrations of ascorbate enhance submaximal epinephrine and
isoproterenol relaxation of trachealis, producing a 3–10-fold increase in sensitivity, preventing tachyphylaxis, and reversing
fade. In vivo, ascorbate improves albuterol’s effect on heaves and produces a 10-fold enhancement of albuterol activity in
‘‘asthmatic’’ sheep.
Conclusions: Ascorbate enhances beta-adrenergic activity via a novel receptor-mediated mechanism; increases potency
and duration of beta adrenergic agonists effective in asthma and COPD; prevents tachyphylaxis; and reverses fade. These
novel effects are probably caused by a novel mechanism involving phosphorylation of aminergic receptors and have clinical
and drug-development applications.
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Introduction
Endogenous allosteric modulators (hereafter ‘‘enhancers’’) of G-
protein coupled receptors that act via extracellular sites are
extremely rare [1] and none have previously been identified for
aminergic receptors such as beta 2 adrenergic receptors (B2AR).
B2AR control the relaxations of bronchioles in the lung. During
asthma attacks, treatment involves exposing these receptors to
epinephrine and related compounds such as albuterol or
isoproterenol to produce dilatation and ease breathing. Persistent
exposure of adrenergic receptors to agonists results in desensiti-
zation of the receptors. The short term fall-off in drug potency is
called fade and probably results from the phosphorylation of the
receptor, putting it into an inactive state. Longer term,
desensitized receptors are internalized into lung cells resulting in
a refractory response to repeated doses of adrenergic agonists, a
phenomenon called tachyphylaxis. Both fade and tachyphylaxis
are problems for patients with asthma and COPD. Fade limits the
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results in less and less effect from any given dose of drug that is
repeated over time. The discovery of compounds that can enhance
adrenergic agonists for asthma treatment could therefore have
many benefits for peoples suffering from asthma and COPD.
The possible utility of adrenergic enhancers for treatment of
asthma and COPD are several. To begin with, there is a gap in
current treatment strategies for these diseases due to the types of
drugs available to patients. Short acting (rescue) inhalers use drugs
such as epinephrine and albuterol that act instantaneously but
persist for only a couple of hours. Long acting inhalers use drugs
such as formoterol and salmeterol that do not begin to have an
effect for an hour or two, but persist for up to twelve hours. Short-
acting and long-acting drugs cannot be used together without risk
of death, so that patients must choose one approach to control of
their disease or the other. Enhancers might be able to convert
short acting rescue inhalers into long acting formulations that still
have immediate efficacy. In addition, enhancers might be able to
decrease adrenergic agonist doses significantly, thereby decreasing
the side effects of beta agonists, which include increases heart rate,
blood pressure, breathing rate, nervousness, and risk of heart
attack and stroke. Less drug translates into less risk.
We are investigating such adrenergic enhancers. We reported
previously that ascorbate can enhance the in vitro alpha adrenergic
activity [2,3] and histaminergic activity [4] of smooth muscle,
independent of the anti-oxidant activity of ascorbate on these
amines. We also demonstrated that this phenomenon is very likely
receptor mediated, since ascorbate binds to the histamine receptor
with a Kd equal to its ability to enhance histamine activity [4]. We
report here that ascorbate, although it has absolutely no effect on
smooth muscle by itself, significantly enhances beta-adrenergic-
mediated smooth muscle relaxation and most likely does so by
means of allosteric modulation of an extracellular site on the
receptor. Using the human beta 2 adrenergic receptor, ascorbate
was found to bind to an outside loop of the receptor, near the
agonist binding site. The enhancement action of ascorbate is not
related to its anti-oxidant activity as the effect is found with drugs
that do not oxidize measurably during the course of the
experiments. Both receptor sensitivity and the duration of action
of beta adrenergic agonists are increased, tachyphylaxis due to
repeated doses of agonists is prevented, and fade can be reversed
by administration of ascorbate. Further, in addition to ascorbate
assisting adrenergic receptor activity, the adrenergic receptor
assists ascorbate’s anti-oxidant activity. The receptor converts
oxidized ascorbate, which is not useful in preventing the oxidation
of other molecules, into its useful, reduced form. Thus, adrenergic
receptors may also have enzymatic activity, controlling their
extracellular environment. [4]. Beta 2 adrenergic enhancement
was demonstrated in both healthy sheep and diseased horses, as
well as in tissues isolated from pigs and guinea pigs. The ascorbate
enhancement of beta 2 adrenergic potency, prevention of
tachyphylaxis, reversal of fade, and the reduction of ascorbate
by adrenergic receptors are all novel findings, reported here for the
first time. We propose that adding ascorbate (or other aminergic
enhancers that we have identified, such as ethylenediaminetetra-
acetic acid and opiates [2–4] at physiological or supraphysiological
concentrations to pulmonary medications may prove highly
beneficial in treating diseases such as COPD and asthma by
permitting the use of lower doses of beta adrenergic agonists,
thereby decreasing the unwanted side effects of these drugs. Since
the ascorbate is delivered directly to the lungs, its enhancement
effects on aminergic compounds are largely limited to the lungs.
The novel receptor-mediated mechanism that we report may also
permit the development of novel combinations treatments or new
tethered drugs that will be more efficacious. Finally, the discovery
of extracellular allosteric modifiers of adrenergic receptors may
permit novel insights into the structures and functions of these
receptor mechanisms.
Results
The effect of ascorbate on beta 2 relaxation of smooth muscle
was measured. Asc at concentrations up to 500 uM by itself had
no effect on guinea pig or porcine trachealis preparations
contracted with acetylcholine (Figure 1). Additional control
experiments in live horses with heaves and sheep treated with
carbachol (see below) showed similarly that there was no
measurable effect of ascorbate by itself in any preparation at any
dose utilized in these experiments.
The effect of ascorbate on beta 2 relaxation of smooth muscle
was next tested in the presence of Epi. Superimposed chart records
of two contractions 6 150 mM Asc are shown in upper part of
Figure 2. Epi produces a significant relaxation in both cases, but
the presence of Epi + Asc results in a deeper relaxation than Epi
alone. Also, the recovery of force within a single contraction,
defined as the fade of the relaxation effect of Epi, occurs more
slowly and to a lesser degree in the presence of Asc than in its
absence. The lower panel of Figure 2 shows the Asc concentration
dependence of the initial relaxation (F2 in the figure) and total fade
(F3 in the figure) in individual contractions, with both showing
significant differences in the physiological Asc range of 40–
100 mM [5]. In Figure 3, using cumulative Epi dose-response
curves on Ach contractions of the pig trachealis, 500 mM Asc plus
Epi produced a significantly greater relaxation than Epi alone at
concentrations of Epi from 0.043 to 1.44 mM.
Figure 4 shows the effect of the supranormal concentration of
500 mM Asc on prolonged Epi-induced relaxation of pig trachealis
Ach-induced contractions. The upper panel shows one of the chart
records of this experiment. The lower panel shows the relative
force at selected times thereafter. The open symbol represents the
force immediately prior to the introduction of Epi. After 3 hours,
during which some oxidation of Epi and ascorbate has presumably
occurred (both are at the top of their dose-response ranges), the
relaxation remains, with no fade occurring. Note in the chart
record that as soon as the Ach, Epi and Asc are washed away, the
tissue immediately relaxes to its pre-contraction level.
In contrast to fade within a single contraction, tachyphylaxis is
the decrease in pharmacological effectiveness in sequential
exposures. In this case, the effect of Asc on the tachyphylaxis of
isoproterenol (IP) was tested using guinea pig trachea. In the upper
panel of Figure 5, a chart record of progressively longer
contractions of Ach + IP (with 0 Asc) for 4, 8, 16, 32, and 64
minutes is shown. There are 10 minute washes between each
contraction. The guinea pig trachea has spontaneous contractions
during washout periods. During the first, 4 minute application of
IP, there is nearly complete relaxation of the tissue. The following
8 minute application also shows nearly complete relaxation to IP.
However, during the 16, 32 and 64 minute applications, the tissue
does not completely relax. It exhibits both immediate tachyphy-
laxis, not reaching the low initial force produced at 4 and 8 minute
applications, and prolonged tachyphylaxis, reaching a plateau at
an even higher force. During identical experiments with 500 mM
Asc included with the IP, shown in the second chart record panel,
the contrast could not be greater. There is no immediate or
prolonged tachyphylaxis to IP. The quantitation of this effect is
shown in the lower panels of Figure 5. Both the lowest force
following IP application, the measurement of the immediate
tachyphylaxis, and the highest force during the IP application, the
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ent between the 0 and 500 mM Asc applications. Importantly,
during post control (PC) contractions after the removal of both IP
and Asc, both conditions return to the control (C) force, indicating
that neither application damaged the tissues.
Figure 6 shows that in addition to blocking IP tachyphylaxis,
Asc also reverses the fade of IP-induced relaxation of the guinea
pig trachea. Both chart records show the same experiment, in
which Ach and IP application produces a profound relaxation of
the trachea, but after 73 minutes, the relaxation has faded. The
addition of Asc, while Ach and IP are still present, renews the
relaxation of the trachea. Quantitatively, for N=7, the 73 minute
fractional force is not significantly different (0.8160.15, SE,
p=0.24) from the force (1.060.0) immediately before IP was first
applied. Both the lowest IP force (0.0560.03) and the force
following Asc (0.0460.02) are significantly different from the
initial application force (p=2610
28 and 7610
28, respectively),
but are not different from each other (p=0.86).
Following the in vitro experiments, we began in vivo measure-
ments of the effect of ascorbate on beta 2 relaxation of pulmonary
smooth muscle with a proof of concept study in horses with the
obstructive airway disease heaves. Baseline D Pplmax, a simple
indicator of lung function than can be made in untrained horses,
did not differ before vehicle or with Asc treatment alone (mean 6
SE, 49.467.9 cm H2O). After inhalation of vehicle, albuterol
decreased the Pplratio in a dose-dependent fashion with maximal
effect achieved at a dose of 360 micrograms (Figure 7).
Pretreatment with ascorbate significantly potentiated the response
to albuterol. In cumulative dose response controls, Asc (0, 5, 10,
and 15 mg/ml) showed no significant effect on Pplmax. Adminis-
tration of atropine (0.02 mg/kg IV) after ascorbate significantly
decreased DPplmax to 20.364.3 cm H2O within 15 minutes
indicating that the horses had the reversible airway obstruction
typical of heaves (data not shown).
Based on these encouraging results from horses with heaves, the
in vivo effect of Asc was investigated more extensively in sheep
Figure 1. Top: Effect of ascorbate (0 to 1.5 mM) on 5 minute force of acetylcholine (3 mM) induced contractions of guinea pig
trachealis. Values are mean 6 SE and N=5. No significant differences (p,0.05) from baseline (0 Asc) were observed over the 5 minute course of the
contractions (exemplars imbedded in figure). Bottom: Effect of ascorbate (500 uM) on 20 min acetylcholine-induced contractions (3 uM) of porcine
trachealis. No effect was observed for an N of 4. For further Asc controls, see Figure 7 (lack of effect of Asc on carbachol-induced bronchoconstriction
in sheep) and Figure 9 (lack of effect of Asc on bronchoconstriction due to heaves in horses).
doi:10.1371/journal.pone.0015130.g001
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ation (Figure 8). In the control trial of Asc without albuterol in the
upper left panel, the airflow resistance was not significantly different
from the carbachol alone challenge at any time point. In the upper
right panel the presence of Asc in 1 breath of albuterol produced a
significantly lower airflow resistance when compared with albuterol
alone. Similar results with 2 breaths of albuterol are shown in the
lower left panel, with Asc improving the ease of breathing. No
measurement of albuterol+ Asc was made at 120 minutesfor either1,
2 or 10 breaths. The lower right panel shows that for the nearly
maximal relief produced by 10 breaths of albuterol, Asc did not
produce a significant difference in relief as measured at times less
than 60 minutes. Figure 9 shows the grouped data for carbachol
alone, carbachol +1 breath of albuterol, carbachol +10 breaths of
albuterol, and carbachol +1 breath of albuterol + Asc. Ascorbate,
which had no effect on carbachol treatment by itself, has a
significantly lower airflow resistance with1 breath of albuterol + Asc
than the resistance of 10 breaths of albuterol alone. The addition of
Asc with the lower level of albuterol produces more relief than
having 10-fold more albuterol.
Having established the in vitro and in vivo ascorbate
enhancement of beta 2 adrenergic relaxation of smooth muscle,
the mechanism of action of ascorbate on the beta 2 receptor was
investigated. Previous research had demonstrated that Asc binds
directly to the histamine receptor on the first extracellular loop [4],
so our hypothesis was that a similar extracellular loop on the
B2AR might also exist. Figure 10 shows the accumulated spectra
of the solutions with the different Asc concentrations in the
presence and absence of human beta 2 adrenergic receptor on the
left, and the difference spectra (Asc and AR combined minus
individual Asc and AR solutions) on the right. In the unprocessed
spectra on the left, six successive spectra over a period of more
than one hour are superimposed as the AR +100 mM Asc, AR
+30 mM Asc, and AR +10 mM Asc lines. The spectra are so
consistent that the individual AR + Asc spectra cannot be
distinguished. Note that in the 100 Asc (with no AR), and to a
lesser extent in the 30 Asc (with no AR), series of lines, the
superimposed spectra are distinguishable, with the Asc absorbance
centered at 266 nm disappearing with time. The difference spectra
on the right show three distinct regions. At 266 nm, the six
Figure 2. Effect of ascorbate on 1 mM epinephrine relaxation of 1 mM acetylcholine contractions of porcine trachealis. Upper panel:
chart records of individual contractions with 0 and 150 mM Asc. F1 is the 5 minute Ach force, at which time Epi is added. F2 is the initial relaxation
produced by Epi. F3 is the steady state force after the fade of the Epi relaxation. Middle Panel: Effect of ascorbate on initial epinephrine relaxation.
Values are mean 6 SE. The open symbol is 0 Asc; the filled symbols are 5–500 mM Asc. Note the log scale for the x axis. The * indicates a significant
difference (p,0.05) from the 0 Asc relaxation. Lower Panel: Effect of ascorbate on the fade of the epinephrine-induced relaxation. Values are mean 6
SE. The open symbol is 0 Asc; the filled symbols are 5–500 mM Asc. Note the log scale for the x axis The * indicates a significant difference (p,0.05)
from the 0 Asc fade.
doi:10.1371/journal.pone.0015130.g002
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posed, forming the thicker upper line in each series. The lower
lines, most clearly seen in the 100 Asc series, are produced as the
Asc is oxidized in the absence of AR. There is a decrease in the
absorbance at 220–230 nm in the 10 mM Asc series, indicating
Asc binding to the AR at this sub-physiological concentration. In
the region centered at 205 nm, there is an Asc concentration
dependent increase in the absorbance, indicating a second binding
of Asc, with this binding in the physiological Asc concentration
range. Note that at 30 and 100 mM Asc, the presence of 1.26 mM
AR is able to virtually stop the oxidation of Asc.
The data obtained from the AR-Asc experiments just described
were compared with identical experiments involving untransfected
cell membranes and AII-transfected cells membranes, previously
published in Dillon, et al. [4]. Asc binding to AR-transfected
membranes was more than five times that observed with the
untransfected and AII-transfected membranes. The decreased
binding was associated with significantly increased Asc oxidation
Figure 3. Top: Effect of 500 mM ascorbate on cumulative epinephrine relaxation (1 mM Epi) of 1 mM Ach contractions of porcine
trachealis at ten minutes following each Epi addition. Values are mean 6 SE. N=4. The * indicates a significant difference (p,0.05) from the 0
Asc data. Bottom: Typical chart recordings showing the effect of of 500 mM ascorbate on cumulative epinephrine relaxation (1 mM Epi) of 1 mM Ach
contractions of porcine trachealis. Asc not only increases the duration of relaxation, but also blunts the acute effects of each cumulative dose
(perhaps because Asc binds to Epi [3,23,24], modulating its availability to the receptor).
doi:10.1371/journal.pone.0015130.g003
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transfected ones [4].
Using the initial addition of seven sets of three wells, the
ambient ascorbate oxidation rate constant was 37.4 minutes, with
a correlation coefficient of 0.96 (Figure 11). For samples exposed
to the UV light of the spectrophotometer, average rate constant is
6.5 minutes, with a correlation coefficient of 0.97. The exposure of
ascorbate to the UV light inside the spectrophotometer increases
the oxidation rate 6-fold. The presence of transfected B2AR
prevents the oxidation of Asc under both conditions.
The binding of ascorbate to peptides with sequences from the
first extracellular loop of the beta 2 adrenergic receptor also
prevents or retards oxidation, as is shown in Figure 12 and Table 1.
All three peptides spanning the loop (amino acids 89–99, 97–106,
and 103–113) showed significant Asc affinity, two centered within
the normal lung Asc range and the third with greater sensitivity
than the highest Asc concentration used in the isolated tissue
experiments. Three peptides with sequences from the insulin
receptor were used as controls. One (157–166) had modest
ascorbate binding, but still weaker than those from the adrenergic
receptor. Two additional insulin receptor peptides (392–404, 425–
433) had much lower Asc affinity, with estimated Kdso f.1500
and 3000 mM. The 89–99 and 97–106 peptides prevented the
oxidation of Asc. Control peptides did not significantly retard or
prevent Asc oxidation.
Discussion
The data above support four novel conclusions. Although
ascorbate has absolutely no effect on airway smooth muscle at
any concentration tested or in any in vitro or in vivo experiment
performed, (1) ascorbate increases the potency of multiple beta 2
adrenergic agonists across a range of species; (2) ascorbate
prevents tachyphylaxis induced by multiple doses of beta 2
adrenergic agonists; (3) ascorbate can reverse fade associated with
long term exposure to beta 2 adrenergic agonists; and (4) the beta
2 adrenergic receptor and peptides derived from its first
extracellular protect ascorbate against oxidation, prolonging its
effects. These observations suggest that the B2AR activity can be
enhanced allosterically by Asc through a novel mechanism that
may provide means to improve the treatment of asthma and
COPD.
The experiments we report here must be interpreted as a set,
each building on previous results. The most important observation
is that ascorbate has no measurable effect on smooth muscle
contractility, on relaxation, or on lung function. The smooth
muscle experiments (Figure 1), those on sheep airway function
(Figure 7), as well as in the data concerning horses with heaves
described in the text, demonstrate that ascorbate has absolutely no
measurable effect on uncontracted, ACh-contracted, or carbachol-
contracted airway smooth muscle in vitro or on lung function in vivo
in four different animal species. We previously demonstrated that
ascorbate has no measurable effect at concentrations up to
500 mM on uncontracted rabbit aorta [2–4].
The absence of ascorbate effect by itself sets the stage for
demonstrating differences in the effects of adrenergic agonists
when they are in the presence of ascorbate compared to when they
are not. We have demonstrated in great detail in previous papers
that the enhancement effects of ascorbate cannot be due to its
antioxidant properties [2–4]. Given the stability of the isoproter-
onol and albuterol used in many experiments reported here,
oxidation cannot be a factor within the time courses of these
experiments and ascorbate cannot be producing its enhancing
effects through prevention of drug oxidation. Ascorbate also has
no effect on acetylcholine- or carbachol-induced contractions, nor,
as we have shown in previous papers on potassium-induced or
angiotensin II-induced contractions [2–4]. Logically, the possible
mechanisms by which ascorbate’s enhancement effects are
produced on smooth muscle must be limited to effects on the
adrenergic system that do not share contractile or relaxile
Figure 4. Effect of 500 mM ascorbate on prolonged 4 mM epinephrine relaxation of 100 nM Ach contraction of porcine trachealis.
Upper panel: chart record of experiment. Lower panel: Values are mean 6 SE. The open symbol is the relative force immediately prior to the
introduction of Epi and Asc. The closed symbols represent values at different times after the introduction of Epi and Asc.
doi:10.1371/journal.pone.0015130.g004
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further limited by the fact that we [2,3] and Herlihy, et al. [6] have
demonstrated previously that ethylenediaminetetraacetic acid
(EDTA) also acts as an enhancer on the adrenergic system.
EDTA is so polar that it cannot enter cells and has no known
receptor or transporter. Since EDTA and ascorbate produce the
same effects, but only one of them can enter cells, we conclude that
the enhancement mechanism is an extracellular one. The only
plausible extracellular mechanism that would permit both
ascorbate and EDTA to produce the same enhancing effect only
on the adrenergic system and only when it is activated, is through
the adrenergic receptor itself.
Figure 5. Effect of ascorbate on tachyphylaxis of 30 nM isoproterenol (IP) relaxation of 1 mM acetylcholine (Ach) contractions of
guinea pig tracheal rings. Upper panels: chart records of progressive contractions in the presence of 0 and 500 mM Asc. The Ach/IP indicates the
addition of Ach and IP. The w indicates the washout of Ach and IP. Lower panels: Quantitation of immediate and prolonged tachyphylaxis. The
immediate tachyphylaxis measurements are plotted as a function of the duration of IP exposure of the immediate prior application. The prolonged
tachyphylaxis measurements are plotted as a function of the duration of the IP application. The C (control) and PC (post-control) in the prolonged
graph (lower panel) are the forces generated by the tissue prior to and following the Ach/IP applications, respectively. Values are mean 6 SE. The
open symbols are 0 Asc; the filled symbols are 500 mM Asc. The * indicates a significant difference (p,0.05) from the 0 Asc data.
doi:10.1371/journal.pone.0015130.g005
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experiments using pig trachealis show that ascorbate lessens, and
at sufficiently high concentration, prevents fade of epinephrine-
induced relaxation of Ach contractions. The ability of ascorbate to
enhance the relaxation occurs within a 100-fold epinephrine
concentration range. Ascorbate also reverses the fade of
isoproterenol-induced relaxation of Ach contractions of guinea
pig tracheal rings, implying that ascorbate will deepen and prolong
the beta agonist effects. Further, guinea pig experiments on
sequential contractions show that ascorbate effectively blocks beta
2 adrenergic tachyphylaxis. Both fade and tachyphylaxis reflect
down regulation of receptor, suggesting that ascorbate prevents
down regulation of beta 2 adrenergic receptors and may, under
some conditions, reverse it (Figures 4, 5, 6).
Figure 6. Ascorbate (500 mM) reversal of the fade of 30 nM
isoproterenol relaxations of 1 mM Ach contractions of twp
separate guinea pig tracheal rings. The solid horizontal line
indicates duration of Ach/IP application. The dashed line indicates the
application of Asc.
doi:10.1371/journal.pone.0015130.g006
Figure 7. Effect of ascorbate on the airflow resistance of intubated sheep. Sheep bronchioles were contracted by carbachol and relaxed
with albuterol. Values are mean 6 SE. The graphs from upper left to lower right are for 0, 1, 2 and 10 breaths of albuterol in the presence and absence
of Asc. The * indicates a significant difference (p,0.05) from the 0 Asc data.
doi:10.1371/journal.pone.0015130.g007
Figure 8. Comparison of effect of 1 breath of albuterol with
ascorbate with 0, 1 and 10 breaths of albuterol on carbachol
induced increases in airway resistance. Values are mean 6 SE. The
* indicates a significant difference (p,0.05) from the 0 albuterol control.
The + indicates a significant difference of the 1 breath of albuterol with
ascorbate from the 10 breaths of albuterol.
doi:10.1371/journal.pone.0015130.g008
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regulation has been observed by those studying down regulation,
but overlooked due to the methods used in most studies. One set of
experimenters study down regulation by exposing cells or
receptors to beta adrenergic agonists in the absence of ascorbate
or EDTA [7], or utilize EDTA in receptor isolation but eliminate
Figure 9. Effect of ascorbate on albuterol relaxation of
breathing resistance in horses with heaves. Values are mean 6
SE. The B indicates the baseline measurement of breathing resistance.
Open circles are measurements of resistance with 0 Asc; filled squares
are measurements with ascorbate. The * indicates a significant
difference (p,0.05) from the 0 Asc data.
doi:10.1371/journal.pone.0015130.g009
Figure 10. Spectroscopic measurements of ascorbate-human adrenergic receptor binding. The figures on the left show the
superimposed records of six spectra collected 118, 141, 155, 188, 199, and 228 minutes after the samples were prepared. Samples with both AR and
ascorbate are indistinguishable from one another and do not change over time, while the ascorbate alone samples show ascorbate oxidation and a
decrease in absorbance in the 266 nm range. The difference spectra in the right hand column show an ascorbate concentration dependent increase
between 190 and 210 nm, an absorbance decrease between 220 and 230 nm at 10 mM ascorbate, and the difference between the oxidizing
ascorbate solutions without AR and the non-oxidizing ascorbate with AR in the 260–270 nm range.
doi:10.1371/journal.pone.0015130.g010
Figure 11. Quantitation of ambient (room) and spectropho-
tometer (UV light exposed) oxidation of ascorbate. Each symbol
represents the average absorbance at 266 nm of 3 wells to which
ascorbate is added. The additions were temporally sequential, with
both the new additions and those from previous additions measured
separately at each subsequent time. The solid symbols, determined by
the first measurement after the addition from a room stock, show the
ambient Asc oxidation. The open symbols show the Asc oxidation of
the seven sets of three wells within the spectrophotometer, with the
data normalized to the initial absorbance of that sample when first
measured in the spectrophotometer. The lines were calculated from a
linearized least squares fit of the data with an absorbance of 0.3 or
greater of the initial absorbance.
doi:10.1371/journal.pone.0015130.g011
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studies utilize concentrations of adrenergic agonists at the top of
their dose response curves or near the highest end of the ranges
that these drugs would be used therapeutically (10 mM isoproter-
enol [8]; 400–700 nM for (-)-epinephrine, 150–300 nM for (-)-
isoproterenol, [9]; 1 uM isoproterenol [7]). Such concentrations
are very close to the concentrations used in our experiments to
produce fade and tachyphylaxis in the absence of ascorbate. In the
absence of ascorbate or EDTA, such experiments will show no
prevention or reversal of down regulation. The second type of
down regulation studies employ ascorbate or EDTA in the assay
procedure at concentrations roughly equivalent (usually 300 mM
25 mM) to those that prevent tachyphylaxis and reverse fade in
our studies and yet down regulation still occurs. Crucially, these
down-regulation studies employ extraordinarily high concentra-
tions of adrenergic agonists that are 30 to 300 times greater than
the concentrations employed in our experiments (e.g., up to
100 mM EPI [10,11]; 10 mM isoproterenol [12,13], or 100 mM
isoproterenol [13]). Such huge concentrations of beta agonists
overwhelm any protective effect of ascorbate or EDTA. The only
group studying down regulation that does not use these very high
concentrations of beta agonists in the presence of (300 uM)
ascorbate employs 1 uM isoproterenol so that one might expect to
observe protection against down regulation. Such protection does
not occur, however, because these investigators add 1 mM of the
phosphodiesterase inhibitor RO-20-1724 to their preparations
Figure 12. Beta 2 Adrenergic Peptides and Ascorbate. Upper panel: binding ascorbate to beta 2 adrenergic receptor and insulin receptor
peptides. The peptide sequences are listed in Table 1. The initial amino acid number of the peptide is listed in the legend. The shaded area represents
the range of the respiratory system concentration of ascorbate in humans (28–40 mM). The vertical line represents 500 mM ascorbate, the highest Asc
concentration used during in vitro experiments herein. Lower panel: prevention of ascorbate oxidation by AR peptides. The * indicates a significant
difference (p,0.05) between the Asc alone absorbance and the Asc absorbance in the presence of the peptide.
doi:10.1371/journal.pone.0015130.g012
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down regulation, and phosphodiesterase prevents or reverses this
down regulation, it is logical to conclude that the antipho-
sphodiesterase compound prevents the up-regulating effects of
ascorbate. These experiments suggest that ascorbate and EDTA
activity may be mediated by putting the receptor in a
conformation that prevents phosphorylation.
Studies on down regulation indicate that the effects of ascorbate
are not a function of its concentration per se, but of the ratio
between its concentration and that of the beta agonist it is
enhancing. A dose relationship between ascorbate and adrenergic
agonists also exists for in vivo enhancement. In healthy sheep with
chemically-induced bronchoconstriction, and in heaves-diseased
horses, ascorbate inhalation improved sensitivity to the beta 2
agonist albuterol but only at submaximal doses of albuterol. The
respiratory system has a lower normal ascorbate concentration
range, 28–40 mM [17], than in plasma, 40–100 mM [5],
presumably due to a higher oxidation rates and inflammatory
processes of disease. This decrease in endogenous ascorbate may
make the lungs particularly amenable to ascorbate treatment in
asthma and COPD.
In light of the receptor mechanism suggested above for Asc
enhancement of adrenergic function, and since Asc modifies
dopamine binding to its receptors [1,18] and binds to the first
extracellular loop of the histamine receptor [4], it was logical to
search for an Asc binding site on the AR that could act
allosterically to modify receptor sensitivity. The main technique
used for these studies was change in spectroscopic absorbance,
which is routinely used to measure binding of molecules.
Experiments involving the binding of Asc directly to isolated
receptor preparations show that the lowest Asc concentration,
10 mM, produces an absorbance change at 220–230 nm
(Figure 10). There is a slight inhibition of alpha adrenergic activity
at this concentration in rabbit aortic tissue [2], not seen in the beta
adrenergic experiments. The binding at physiological concentra-
tions and higher (ca. 50 uM) occurs in the 190–210 nm range.
The presence of a single homologous region shared by Asc
transporters and three classes of aminergic receptors that are
enhanced by Asc (Figure 12, upper panel) suggested that
extracellular loop regions of the receptors might be responsible
for their Asc sensitivity. The location of the binding site also
provides a plausible mechanism by which Asc enhances AR
activity. Epi binding to AR is mediated by a series of specific
amino acid interactions involving His 79, Asp 113, Ser 203, Ser
204 and Ser 207 [19,20]. The ascorbic acid transporter-like region
is immediately adjacent to the adrenergic binding site and overlaps
the disulfide bond between Cys 170 (second loop) and Cys 106
(first loop) that is required to form the high affinity form of the
receptor (Figures 13, Figure 14) [20–22]. Ascorbic acid may help
to maintain this critical disulfide bond by protecting it from
oxidation, and it may further define the molecular structure of the
adrenergic binding site itself, perhaps trapping agonists in the
pocket formed with the second extracellular loop [22]. The
stabilization of the Cys 106 residue by polarization of nearby
amino acid residues helps form the high affinity state of the beta 2
AR [21]. The presence of an ascorbate binding site immediately
adjacent to, and perhaps overlapping, this disulfide bond
represents a logical and novel mechanism for mediating high
affinity receptor activity.
Normally, upon binding an adrenergic agonist, the AR is
rapidly desensitized on the order of seconds to minutes by
phosphorylation carried out by beta adrenergic receptor kinase
(bARK) [7–16]. bARK is activated by conformational changes in
the AR upon agonist binding [7–16]. We propose that Asc binding
may prevent the conformational change in the AR receptor
necessary for bARK activation, thereby maintaining the AR in its
high sensitivity conformation for extended periods of time.
Experimentally, Asc should therefore significantly retard agonist-
stimulated phosphorylation of the AR, as has previously been
demonstrated for combinations of agonists with antagonists [23]
and chronic beta-blockers [24]. Moreover, it is possible that once
the AR is phosphorylated, binding of Asc to it (in the presence of
agonist) may permit a receptor conformation modification that
causes rapid dephosphorylation of the receptor, returning it to its
high sensitivity state. The necessity to employ a phosphodiesterase
inhibitor in order to measure desensitization by normal concen-
trations of adrenergic enhancers in the presence of ascorbate [14–
16] can be interpreted as evidence that ascorbate indeed does
prevent and even reverse phosphorylation of the receptor. Such a
mechanism would explain our ability to reverse fade rapidly
(Figure 6) since desensitization due to phosphorylation takes only a
matter of seconds and can presumably be reversed on the same
time scale. Notably, Parra, et al. [25] have also reported
immediate reversal of fade in rabbit aortic smooth muscle
preparation stimulated with adrenergic agonists and enhanced
with an opioid agonist, and several groups have reported reversal
of tachyphylaxis in human patients with steroids e.g. [26,27].
The receptor spectra also reveal the striking finding that the
receptor can either prevent Asc oxidation or possibly recycle
dehydroascorbate back into Asc. As Figure 10 shows, ascorbate up
to 100 mM does not oxidize when AR is present at 1.26 mM, even
under UV spectroscopic conditions where Asc is oxidized more
rapidly than under ambient conditions. The concentration
difference between ascorbate and AR is so great that simple
binding alone cannot explain the prevention of ascorbate
oxidation. Ascorbate must be reduced by AR at a rate faster than
the rate of oxidation (Figure 10). We infer that the adrenergic
receptor, like the histamine receptor [4] may have enzymatic
Table 1. UV spectroscopy was used to determine the binding
constants of ascorbic acid binding to various synthetic
peptides derived from the first extracellular loop of the
human beta 2 adrenergic receptor (B2AR).
Peptide Sequence Kda R
2 Kd
(mm)* (mm)
D1DR 89–100 FWPFGSFCNIWV .3000 estimated
B2AR 89–99 FGAAHILMKMW 60 0.998 22
B2AR 97–106 KMWTFGNFWC 57 0.96 19
B2AR 103–113 NFWCEFTSID 266 0.968 232
INSR 157–166 TIDWSRILDS 903 0.995 861
INSR 392–404 SGYLKIRRSYALV .1500 estimated
INSR 425–433 YSFALDNQN .3000 estimated
This loop had been identified as being homologous to the sodium-dependent
ascorbic acid transporter (Figure 13), and therefore likely to bind ascorbate.
Control peptides were derived from the human insulin receptor (IR) and human
dopamine D1 receptor, which lacks homology at this site for the ascorbic acid
transporter. The Kd is the binding constant. The Kda is the ascorbate
concentration where K of the peptide is bound. Rate constants were calculated
from a linearized least-squares fit to an exponential decay where R
2 is a
measure of the fit of the calculated equation to the data. The highest affinity
peptides share only one short sequences, which KMW, suggesting that this
motif is the main component of the Asc binding site. Peptides that lack this
motif have little or no Asc binding.
*Kda is the ascorbate concentration where K of the peptide is bound.
doi:10.1371/journal.pone.0015130.t001
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extracellular environment. This oxidation-reduction cycle between
Asc and the first extracellular loop mimics the well-characterized
oxidation-reduction cycle of Asc with glutathione, another Cys-
containing peptide [28]. We are currently characterizing this
ascorbate-AR peptide oxidation-reduction system in much more
detail and preliminary data show that peptides derived from the
first extracellular loops of B2AR and the histamine receptor are
able to recycle Asc just as efficiently as glutathione on a mole-to-
mole basis (unpublished data). The binding of Asc to Epi
[2,4,29,30] and to specific amino acid residues would form an
evolutionarily advantageous integrated system of interactions
useful to AR receptor activation and to maintenance of reduced
ascorbate. It is intriguing to consider the possibility that other such
antioxidant or vitamin-associated receptor systems linking agonist-
cofactor interactions may exist.
We note that the adrenergic receptor-mediated mechanism for
Asc enhancement investigated here may be supplemented by other
mechanisms. In addition to smooth muscle contraction, closure of
the periphery of the lung has been reported to an important factor
in asthma in humans [31] and mice [32]. Moreover, beta agonists
may reduce lung vascular permeability and increase secretion of
lung surfactants [33,34]. The present study did not examine
closure of the periphery, lung vascular permeability or lung
surfactant secretion, so future studies will be needed to explore the
degree to which ascorbate enhances or alters these phenomena.
We stress that no adverse effects of ascorbate inhalation were
observed in either horses or sheep during or after our experiments.
Moreover, there is good reason to believe that the clinical
enhancement of albuterol observed in our experiments is largely or
completely limited to the trachea and bronchioles. Although some
ascorbate will be absorbed into the blood stream, just as some
albuterol is absorbed, the effect of the additional ascorbate on
endogenous concentrations of ascorbate will be inconsequential.
Even if all of the ascorbate delivered via the lungs to a horse or
sheep were to be absorbed into the blood stream instantaneously,
the overall rise in serum ascorbate would be less than two percent,
which would have negligible effects on systemic aminergic
function. Thus, the sheep data (Figures 7 and 8) suggest that
ASC may allow the dose of adrenergic drug to be dropped more
than ten fold, retaining therapeutic efficacy, but also reducing
systemic side effects such as the increased blood pressure,
increased heart rate, nervousness, and sleeplessness that often
accompany adrenergic inhaler use.
Both carbachol-treated sheep and horses with heaves are well-
characterized models for human airway disease so that the results
reported here may have practical applications to the treatment of
human asthma, chronic obstructive pulmonary disease, and
Figure 13. Adrenergic receptor amino acid sequences. Upper panel: adrenergic receptor and sodium-dependent ascorbate transporter
homology. The amino acids of the human beta 2 AR and human alpha 1A AR are compared with the human SVC1 and SVC2 ascorbate transporters.
The solid lines indicate exact matches, and the: indicates similar amino acid substitutions. Lower panel: 2-D model of relative amino acid positions in
the N-terminal section of the human beta 2 AR. The solid squares indicate the cysteines that must form a disulfide bond in order for epinephrine to
bind, and the solid diamonds indicate the amino acids that form the epinephrine binding site. The thick solid line indicating the ascorbate-binding
site is in close proximity to the both the cysteines and the epinephrine binding site. Peptides listed in Table 1 were derived from the homologies
displayed here.
doi:10.1371/journal.pone.0015130.g013
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combination may fill a current therapeutic need. Existing beta
adrenergic drugs for asthma and COPD are either quick onset,
short-duration drugs (e.g., albuterol and epinephrine) used as
‘‘rescue inhalers’’, or slow onset, long-duration drugs (e.g.,
formoterol and salmeterol) that do not address an ongoing asthma
attack. Our data suggest the possibility of producing quick-onset,
long-duration drugs [2–4,35]. We believe that such enhanced
drugs might avoid some of the serious health risks posed by
formoterol and salmeterol. In our view, the problem with current
long-acting beta-agonists is two-fold: 1) they have very slow onset
leaving asthmatics open to acute asthma attacks during the first
couple hours after treatment; 2) these acute asthma attacks cannot
then be treated effectively because immediate onset adrenergic
agonists (rescue inhalers) synergize with the slow-onset, long-acting
ones greatly increasing risk of stroke and heart attack. Enhanced
formulations [2–4,35] of quick onset beta agonists may avoid these
risks by maintaining their quick onset (Figures 7 and 8) yet
producing long-acting effects (Figures 3 and 4). Moreover, it may
be possible to use an ascorbate inhaler to supplement adrenergic
inhalers, or even intravenous ascorbate in the cases of hospitalized
patients resistant to adrenergic treatment, to prevent tachyphylaxis
or to reverse fade (Figures 5 and 6). The observation that
enhancement is accompanied by prevention of tachyphylaxis and
reversal of fade suggests further that it might be possible to
formulate novel therapeutics that do not have the rebound effect
(rhinitis medicamentosa) that current adrenergic decongestants
display, or that obviate the paradoxical pharmacology document-
ed by Bond [24] with regard to the use of beta blockers in asthma.
In addition, the discovery of Asc enhancement of adrenergic
activity may be of utility beyond airway disease since adrenergic
drugs have a wide range of medical uses. The Asc binding site
characterized here on the human B2AR is conserved in all AR
types (Figure 12), the histamine receptor [4] and dopamine
receptors, and in all mammalian species sequenced. We have
already demonstrated similar enhancement of alpha-adrenergic-
induced contractile effects on aortic preparations in vitro [2,3] and
of histamine receptor-mediated contractile effects on aortic
preparations in vitro [4]. Data from human drug trials show that
ascorbate produced a three-fold increase in the inotropic effect of
dobutamine [36]; a two- to three-fold increase in intraduodenal
isoproterenol activity [37]; a similar increase in vasodilation
caused by endogenous catecholamines in veins [38]; and an
increase in phenylephrine induced cardiovagal baroreflex sensi-
tivity in older men [39].
One problem that may attend the systemic delivery of Asc or
other enhancers (as opposed to direct delivery to the nasal mucosa,
sinuses, or airway) is the risk of enhancing all endogenous amines,
which may create risks such as high blood pressure, tachycardia,
and stroke. We have demonstrated that phenylpropanolamine
taken with megadoses of oral Asc could produce sufficient
increases in smooth muscle contraction to be fatal [2]. Thus,
tethered compounds that link Asc or other enhancers to specific
aminergic drugs so that enhancement is mediated only at specific
receptor subtypes will be a preferred direction for the development
of future drugs [35].
In sum, we report a novel receptor-mediated enhancement of
beta adrenergic drugs that increases duration of drug activity and
receptor sensitivity, prevents tachyphylaxis, reverses fade, has clear
clinical applications to the treatment of asthma and COPD, and
has wider drug development implications for many drugs targeted
at aminergic receptors. We propose that these effects are mediated
by a novel mechanism.
Materials and Methods
All experiments involving animals were approved by the
appropriate university animal use committee: Michigan State
University for pigs, guinea pigs and horses, the University of
Miami for sheep.
Isolated tissue experiments
Physiological salt solution (PSS) contained (in mM) 116 NaCl,
5.4 KCl, 19 NaHCO3, 1.1 NaH2PO4, 2.5 CaCl2, 1.2 MgSO4, and
5.6 glucose. PSS was aerated with 95% O2-5% CO2 to maintain
pH 7.4 and warmed to 37uC before addition to tissue baths.
Distilled and filtered water with a resistance of 17 MV was used for
all experiments. Smooth muscle strips were prepared from porcine
trachealis collected at slaughter. The trachealis was cut from the
trachea, the epithelium and lamina propria were pealed away, and
106362 mm strips cut with a dissecting scissors and a single edge
razor blade. The strips were attached to a micrometer and force
transducer using Plexiglas-stainless steel clips and mounted in
tissue baths. [2] The strips were bathed in physiological salt
solution (PSS) at 37uC and bubbled with 95% O2/5% CO2. After
the strips were mounted, each was stretched to 5 g and allowed to
stress relax for 2 h before activation. If stress relaxation reached
0 g, the ring was restretched to 2 g and allowed to stress relax until
the passive force was stable. This procedure leaves the strips near
their optimal length for force development. Then, prior to any
experimentation, each strip was pre-contracted with K+ for at
least 10 min, at which time prewarmed PSS was used to wash out
the contracting solution. Relaxation to baseline typically took
10 mins or so. In addition, before experimentation began, each
strip was contracted with a prewarmed 3 mM solution of ACh.
This procedure was repeated at the ending of each day’s set of
experiments to ensure that force contraction was maintained
stably throughout the experiments. Strips that did not respond
appropriately to K+ or ACh initially were discarded and data from
Figure 14. 3-dimensional model of the ascorbate binding
region of the adrenergic receptor. The position of the ascorbate
binding site (highlighted in blue beneath the arrow) is immediately
adjacent to the adrenergic binding site. (Model provided by, and
adapted, with permission from Lei Shi and Jonathan A. Javitch,
Columbia University College of Physicians and Surgeons, and reprinted
from the Annual Review of Pharmacology and Toxicology, volume 42 
Annual Reviews www.annualreviews.org) [22].
doi:10.1371/journal.pone.0015130.g014
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across an entire set of experiments were not used.
Acetylcholine (Ach) and ascorbate (Asc) were prepared as
refrigerated stocks in PSS until mixed for pre-warming and
aeration immediately prior to introduction into the tissue baths.
The strips were contracted, as shown in Figure 1, with 1 mMo r
100 nM Ach 6 different concentrations of Asc. After 5 minutes,
1 mM Epi was added by syringe from a 1 mM refrigerated stock
solution. For the guinea pig experiments, 300–400 g male animals
were anesthetized via halothane inhalation, stunned and exsan-
guinated by severing the major blood vessels. [40] The trachea was
removed and kept in ice-cold PSS until dissection. Tracheal rings
of 2 mm width were cut with a single edge razor blade and the
rings suspended on loops attached to the micrometer and force
transducer system described above. The rings were stretched for at
least two hours and pre-contracted with K+ and ACh before
experimentation was begun, as described above. The rings were
stimulated with 1 mM acetylcholine (Ach) and relaxed with 30 nM
isoproternol (IP) in the presence or absence of 500 mM ascorbate.
All tissues were weighed to the nearest 0.1 mg at the conclusion of
the experiment.
In vivo experiments
Tests of the enhancement effect of Asc on beta-adrenergic
relaxation of pulmonary tissue were tested on horses and then
sheep. The effect of Asc was tested in six horses with heaves, an
asthma-like inflammatory obstructive airway disease similar to
chronic obstructive pulmonary disease. The main cause of airway
obstruction in heaves is cholinergically-mediated bronchospasm
that is provoked by feeding hay, the dust from which initiates
inflammation and airway obstruction [41]. In unsedated horses, an
esophageal balloon connected to a pressure transducer and
physiograph measured esophageal pressure which reflects pressure
in the pleural cavity [42]. The severity of obstruction was
evaluated from the change in pleural pressure during tidal
breathing (DPplmax) and experiments were conducted on un-
sedated horses when DPplmax was greater than 20 cm H2O [43].
The aerosol of ascorbate or vehicle generated by an ultrasonic
nebulizer was delivered to the horse by means of a non-
rebreathing valve and facemask. Albuterol was administered from
a metered dose canister by means of a commercially available
inhaler designed for horses (Torpex, Boehringer-Ingelheim
Animal Health, St. Joseph, MO) [44,45]. In a randomized
crossover experiment, 6 heaves-affected horses were treated with
vehicle or ascorbate (1 ml/min of 15 mg/ml Asc solution by
nebulizer for 4 minutes) before administration of albuterol (120,
240, 360, and 720 micrograms). The DPplmax was measured at
baseline, 15 minutes after the end of vehicle/ascorbate adminis-
tration and 15 minutes after each dose of albuterol and the data
were expressed as the Pplratio, i.e. the ratio of DPplmax after drug
dose to DPplmax at baseline. At the conclusion of the experiments,
the horses were given atropine (0.02 mg/kg IV) to test for
reversibility of airway obstruction.
A total of 6 sheep (31–43 kg), with documented airway
hypersensitivity to Ascaris suum antigen were used. The sheep were
conscious and were restrained in a modified shopping cart in the
prone position with their heads immobilized. Anesthesia of the
nasal passages with topical 2% lidocaine was achieved and a
balloon catheter was advanced through one nostril into the lower
esophagus. The animals were intubated with a cuffed endotracheal
tube through the other nostril as previously described. [46–48]
Breath by breath determination of mean pulmonary airflow
resistance (RL) was measured with the esophageal balloon
technique described extensively. [6–8] The mean of at least 5
breaths, free of swallowing artifact, were used to obtain RL in
cmH2O6L
216sec. All aerosols were generated using a disposable
medical nebulizer (Raindrop
R, Nelcor-Puritan Bennett, Carlsbad,
CA). Aerosols were delivered at a tidal volume of 500 ml and a
rate of 20 breaths per minute [46–48]. RL was measured at
baseline and then immediately after 10 breaths of 2.0% w/v
carbachol. The sheep then received a specified number of breaths
of aerosol albuterol or ascorbate + albuterol at 15 min, 30 min,
1 h and 2 h after the carbachol challenge. RL was measured
immediately after each treatment. A control trial was conducted in
the same manner except that following carbachol challenge
ascorbate alone (10 breaths of 15 mg/ml Asc solution) was given
at each time point.
Isolated receptor experiments
The availability of human beta 2 adrenergic receptor (Sigma)
allowed direct experiments of the effect of Asc on the receptor.
The human adrenergic receptor (AR) is available at 31.4 mMi na
solution of 50 mM Tris, 10% glycerol and 1% BSA at pH 7.4.
Ascorbate was prepared as a 500 mM stock in 20 mM sodium
phosphate buffer at pH 7.4. Triplicate samples of 250 ml
containing 0, 10, 30 and 100 mM Asc 6 1.26 mM receptor were
prepared. The amount of adrenergic receptor buffer and
phosphate buffer were constant in all samples. 200 ml of each
sample were added to a 96 well plate and spectra collected from
190–310 nm in 1 nm increments during a series of repeated
readings over a period of 2 hours in a Spectramax spectropho-
tometer. Difference spectra were used to measure the effect of the
receptor on ascorbate over time. The data obtained here were
compared with similar data obtained in a previous set of
experiments reported in Dillon, et al. [4] using Angiotensin II
transfected membrane (A2M) and untransfected membrane
(UTM), which were obtained from Novascreen Biosciences
(Hanover, Maryland) and prepared identically to the AR.
Ascorbate oxidation
Since adrenergic receptors alter the rate of Asc oxidation in the
spectrophotometer, we sought to ascertain the basal Asc oxidation
rate in the spectrophotometer compared with the ambient Asc
oxidation rate on the counter top. Asc oxidation can be measured
in the spectrophotometer, using the ascorbate peak centered at
266 nm. As Asc is oxidized to DHA, this peak decreases, since
DHA does not absorb at this wavelength. Ascorbate oxidation
rates were measured using a Spectramax scanning spectropho-
tometer. 200 ml samples of ascorbate (0.1 mM stock in 20 mM
sodium phosphate) were added to each of three wells in a crystal
plate and scanned in the spectrophotometer. Every three minutes,
another set of three wells in the plate were filled with 200 mlo f
ascorbate and the plate (including the previous sets of three wells)
scanned again. Altogether, 24 wells were scanned from 230–
300 nm at 2 nm increments. The Asc oxidation rate was
determined by measuring changes in the Asc peak at 266 nm.
The rate at which Asc oxidized during exposure to UV light in the
spectrophotometer was compared with the rate at which Asc
oxidized under ambient conditions. The ambient Asc oxidation
rate was calculated using the initial absorbance of the fresh
addition of Asc to the different wells, since prior to the initial
measurement all their oxidation had taken place outside the
spectrophotometer. The ambient temperature was 23.9C and the
temperature inside the spectrophotometer was 24.8C. Rate
constants were calculated from a linearized least-squares fit to an
exponential decay using the Axum data processing software. In
each case, a correlation coefficient for the rate constant was
determined.
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A series of overlapping peptides (Table 1) synthesized by the
Macromolecular Synthesis Facility at Michigan State University
were tested for Asc binding using the same UV spectroscopy
methods described above. The peptides synthesized included three
spanning the first extracellular loop of the beta 2 adrenergic
receptor (amino acids 89–99, 97–106, and 103–113) and three
from the insulin receptor as controls. The best fit of the data to the
Hill equation was used to determine the apparent dissociation
constant Kda. The actual Kds in Table 1 are calculated from
Kd=K da20.5[peptide concentration]. The effect of the peptides
on Asc oxidation was measured using 50 mM peptide and 62.5 mM
Asc in 50 mM potassium phosphate at pH 7.4. The Asc
absorbance was measured at 266 nm over time in the presence
and absence of the 89–99 and 97–106 peptides.
Statistics
For repeated measures in which only two tests, with and without
ascorbate, were performed on the same tissue or animal, a two-
way ANOVA without replication was performed [49]. For the
tests of relaxation and fade in porcine tracheal strips (Figures 1 and
2), each ascorbate/epinephrine concentration effect was individ-
ually compared with the relaxation and fade caused by
epinephrine alone. Similarly, the reversal of isoproterenol fade
(Figure 6) compares subsequent forces to the force immediately
preceding the IP application. The ANOVA for these comparisons
is mathematically equivalent to a t-test. The two-way ANOVA
without replication was used to determine differences in the dose-
response curves in the presence and absence of ascorbate for the
effects of epinephrine on porcine trachealis force/cross-sectional
area (Figure 3), isoproterenol-induced tachyphylaxis of guinea pig
tracheal rings (Figure 5), and albuterol relaxation of sheep
(Figures 7 and 8) and horse (Figure 9) airways. For comparison
of ascorbate oxidation in the presence of peptides, a two-way
ANOVA with replications (N=3 at each time), was performed.
For all tests, p,0.05 value was considered indicative of a
difference between the tested groups.
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